ClinicalTrials.gg
CompletedNCT03439098Updated Aug 14, 2019

Effects of Fermented Codonopsis Lanceolata on Improvement in Cognitive-Bio-Markers of Cognitive Functions

An interventional study of Fermented Codonopsis lanceolata 525mg and Fermented Codonopsis lanceolata 1050mg in Subjective Memory Complaints, sponsored by Ewha Womans University. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-14.

Sponsored by Ewha Womans University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2015, registered Dec 2015).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to demonstrate the cognitive enhancement effect and safety of Fermented Codonopsis lanceolata, using the cognitive and clinical indicators (e.g. memory, attention, and psychomotor speed) and the latest brain imaging methods for healthy adults suffering subjective cognitive impairment.

02

Conditions studied

  • Subjective Memory Complaints
03

In context

Lead sponsor

Ewha Womans University is the lead sponsor of 41 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 20 and 65 years old
  • Global Deterioration Scale score (GDS) of 2
  • High school or higher levels of education
  • With

Exclusion criteria

Exclusion Criteria:

  • Evidence of neurologic or medical conditions
  • Axis I diagnosis when assessed by the board certified psychiatrist using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorder, 4th edition ()(SCID-IV)
  • Mini-mental status examination score of 25 or less
  • Clinical Dementia Rating score of 0.5 or more suggesting cognitive impairment beyond self-perceived subjective deficits
  • Intelligence quotient less than 70
  • Any history of head trauma involving loss of consciousness or seizure
  • to magnetic resonance imaging (MRI)
  • Use of psychotropics in last 3 months
  • Allergic adverse reactions to Fermented Codonopsis lanceolata
  • Participation in other clinical trials during the study period that might affect the outcome of the present study
  • Use of oral medication
  • Current pregnancy or breast-feeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Fermented Codonopsis lanceolata 525mg

    Fermented Codonopsis lanceolata 525mg/day

    Dietary Supplement: Fermented Codonopsis lanceolata 525mg

  • Experimental
    Fermented Codonopsis lanceolata 1050mg

    Fermented Codonopsis lanceolata 1050mg/day

    Dietary Supplement: Fermented Codonopsis lanceolata 1050mg

  • Placebo comparator
    Placebo

    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementFermented Codonopsis lanceolata 525mg

    Fermented Codonopsis lanceolata 525mg daily for 8 weeks

  • Dietary supplementFermented Codonopsis lanceolata 1050mg

    Fermented Codonopsis lanceolata 1050mg daily for 8 weeks

  • Dietary supplementPlacebo

    Placebo daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Changes in standardized scores on a neuropsychological test battery

    A composite z-scores were calculated from the scores of the neuropsychological test battery on attention and working memory. The test battery included Letter-number sequencing, Digit span (forward), and tasks from the Cambridge Neuropsychological Test Automated Battery (CANTAB) including the Match-to-Sample Visual Search, Reaction Rime, Rapid Visual Information Processing, and Stop Signal tasks.

    Time frame: baseline, 4th week, 8th week

Secondary outcomes

  1. Changes in scores of the Subjective Memory Complaints Questionnaire

    The Subjective Memory Complaints Questionnaire (SMCQ) contains 14 items and consists of two domains: global memory function and everyday memory function. The response to each item is rated as "yes" (1 point) or "no" (0 point). The total score ranges from 0 to 14 points, and higher points indicate larger degrees of subjective memory complaints.

    Time frame: baseline, 4th week, 8th week

  2. Number of participants with adverse events

    Time frame: 4th week, 8th week

  3. Changes of brain volume in magnetic resonance imaging assessed by computational approaches

    Volumes of the clusters in the brain are reported in cubic millimeters

    Time frame: baseline, 8th week

  4. Changes of cortical thickness in magnetic resonance imaging assessed by computational approaches

    Cortical thickness is measured in millimeters.

    Time frame: baseline, 8th week

  5. Functional brain changes in magnetic resonance imaging assessed by computational approaches

    The Blood Oxygenation Level Dependent (BOLD) signal intensities in arbitrary units are measured in each voxel of the brain. These values are compared between the time points and groups, and the statistical values are presented as results.

    Time frame: baseline, 8th week

  6. Metabolic brain changes in magnetic resonance imaging assessed by computational approaches

    Brain metabolite concentrations are assessed using the magnetic resonance spectroscopy and are estimated in mmol per liter.

    Time frame: baseline, 8th week

07

Study locations

1 site
  • Ewha Womans University
    Seoul, 03760, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in May 2016, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2015
First posted
Feb 20, 2018
StartActual
Jul 6, 2015
Primary completionActual
May 19, 2016
CompletionActual
May 19, 2016
Last update
Aug 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03439098
Lead sponsor
Ewha Womans University
Responsible party
In Kyoon Lyoo (Professor, Ewha Womans University) — Principal investigator
First posted
Feb 20, 2018
Start date
Jul 6, 2015
Primary completion
May 19, 2016
Completion
May 19, 2016
Last update
Aug 14, 2019

Study contacts

Inkyoon Lyoo, MD, PhD, MMS
principal investigator · Ewha Womans University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion